Mode
Text Size
Log in / Sign up
N/A N=9 Treatment

Purine Analog-Based Conditioning in Patients With Severe Aplastic Anemia

Aplastic Anemia

Enrolled (actual)
9
Serious AEs
66.7%
Results posted
Oct 2011
Primary outcome: Primary: Number of Patients With Engraftment Response — 9 Participants

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Fludarabine (Drug); Cyclophosphamide (Drug); Antithymocyte Globulin (Drug)
Age
Pediatric, Adult, Older Adult
Sex
All
Sponsor
M.D. Anderson Cancer Center
Primary completion
Aug 2009

Outcome Measures

OutcomeResultp-value
PRIMARY
Number of Patients With Engraftment Response
9

Summary

Primary Objectives: 1. To determine the feasibility and toxicity of employing purine-analog based conditioning for allogeneic donor stem cell transplantation in patients with severe aplastic anemia (AA). 2. To determine the engraftment kinetics and degree of chimerism that can be achieved with this strategy.

Eligibility Criteria

Inclusion Criteria

  • Patients up to 70 years of age with a diagnosis of severe AA (Camitta et al., 1979) and a matched unrelated donor who are unresponsive to IS or who have relapsed after an initial response to IS. Patients with a diagnosis of SAA and an human leukocyte antigen (HLA) - compatible sibling donor are eligible only if they are 40 years of age or older (up to age 70) and regardless whether they have received IS or not. Patients with primary or secondary graft failure following autologous or allogeneic stem cell transplant are eligible.
  • Patients must have a serum bilirubin of 2 mg/dl or less, serum creatinine 12 weeks). Left ventricular ejection fraction > 40%, no uncontrolled arrhythmia or symptomatic cardiac disease. Forced Expiratory Volume in 1 Second (FEV1), Forced Vital Capacity (FVC) and Carbon Monoxide Diffusing Capacity (DLCO) > 40%. No symptomatic pulmonary disease. Negative pregnancy test.
  • Patients must have an HLA-compatible related or unrelated donor willing to donate marrow or rhG-CSF-mobilized peripheral blood stem cells. In the event of transplants from matched unrelated donors, a high-resolution allele match for HLA-A, -B, -C, -DRB1 and DQB1 ("10 of 10 match") is preferred. However, a one-antigen mismatch ("micromismatch") is also considered acceptable matching ("9 of 10 match").
  • Patients must sign informed consent. In the event of a pediatric patient (i.e., a minor), consent will be provided by their guardian/parent.
  • Lack of clonal cytogenetic abnormalities associated with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) or other hematologic malignancies.

Exclusion Criteria

  • Life expectancy of less than 8 weeks. Inability to provide informed consent.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00427336). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search